The phase 3 LUCIA clinical trial of Duravyu for wet age-related macular degeneration has started, following the phase 3 LUGANO trial. Both trials are assessing the safety and efficacy of Duravyu, a sustained-release intravitreal insert that delivers vorolanib, in patients with wet AMD. Approximately 400 patients will receive either Duravyu or an aflibercept control in each trial, with injections every 6 months. The primary endpoint is the change in visual acuity at weeks 52 and 56 compared to baseline. EyePoint Pharmaceuticals, the company behind Duravyu, is optimistic about the results and the potential impact on patients with retinal diseases.
Source link
Patient dosing underway in phase 3 LUCIA trial of Duravyu for wet AMD
